Entrada net loss narrows 0.79% to $42.76 million in Q2 FY26 - TRDA News | RalliesEntrada net loss narrows 0.79% to $42.76 million in Q2 FY26
T
TRDA• Quarterly results
- Entrada Therapeutics posted a Q2 net loss of $42.8 million, versus a $43.1 million loss a year earlier.
- Collaboration revenue slid 53.95% to $898,000; R&D expense eased 6.62% to $35.4 million.
- Cash, cash equivalents and marketable securities fell to $223 million from $295.7 million at Dec. 31; runway seen into Q3 2027.
Clinical program updates
- Enrollment completed for ELEVATE-44-201 Cohort 2; Cohort 1 open-label data due by year-end 2026, Cohort 2 data expected Q1 2027.
- ELEVATE-45-201 Cohort 1 data due in October 2026; Vertex expects VX-670 Phase 1/2 data in DM1 in H2 2026.
RVTY
•
